
Peer reviewed version

Link to published version (if available):
10.2337/dc12-1712

Link to publication record in Explore Bristol Research
PDF-document

This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version is available online at DOI: 10.2337/dc12-1712.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Early onset, co-existing autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down’s syndrome.

Short title: Diabetes in Down’s syndrome

Rachel J Aitken BSc
Kay L Mehers PhD
Alistair J Williams BSc
Jamie Brown BSc
Polly J Bingley MD
Reinhard W Holl PhD
Tilman R Rohrer PhD
Edith Schober MD
Majedah M. Abdul-Rasoul MD
Julian PH Shield MD
Kathleen M Gillespie PhD

1School of Clinical Science at North Bristol, University of Bristol, UK
2Institute of Epidemiology and Medical Biometry, University of Ulm, Germany
3Department of Paediatrics and Neonatology, Saarland University Medical Centre, Homburg, Germany
4Department of Paediatrics, Medical University of Vienna, Vienna, Austria
5Pediatric Endocrine Unit, Mubarak Alkabeer Hospital, Kuwait City, State of Kuwait

Corresponding author:
Dr KM Gillespie
Learning and Research,
Southmead Hospital
Bristol BS10 5NB
UK
Fax: +44 117 959 5336
Tel: +44 117 959 5337
e-mail:K.M.Gillespie@bristol.ac.uk

Key words: Down’s syndrome, diabetes, HLA class II genes, islet autoantibodies

Manuscript Total Word Count: (Abstract 250)

No of Tables:1; No of Figures 2
ABSTRACT

Objective: Down’s syndrome (DS) is associated with an increased risk of diabetes, particularly in young children. HLA-mediated risk is however decreased in children with DS and diabetes (DSD). We hypothesised that early-onset diabetes in children with DS is aetiologically different from autoimmune diabetes.

Research design and methods: Clinical and immunogenetic markers of autoimmune diabetes were studied in 136 individuals with DSD and compared with 194 age and sex-matched individuals with type 1 diabetes, 222 with DS and 671 healthy controls. HLA class II was analysed by PCR-SSP. Islet autoantibodies were measured by radioimmunoassay.

Results: Age-at-onset of diabetes was biphasic with 22% of DS children diagnosed before age 2 years, compared with only 4% in this age group in type 1 diabetes in the general population (p<0.0001). The frequency of the highest risk type 1 diabetes-associated HLA genotype DR3-DQ2/DR4-DQ8 was decreased in both early and later onset DSD compared with age-matched children with type 1 diabetes (p<0.0001) although HLA DR3-DQ2 genotypes were increased (p=0.004). Antibodies to GADA were observed in all 5 samples tested from children diagnosed ≤ 2 years and persistent islet autoantibodies were detected in 72% of DSD cases. Thyroid and celiac disease were diagnosed in 74% and 14% respectively of the DSD cohort.

Conclusion: Early-onset diabetes in children with DS is unlikely to be aetiologically different from autoimmune diabetes occurring in older DS children. Overall these studies demonstrate more extreme autoimmunity in DSD typified by early onset diabetes with multiple autoimmunity, persistent islet autoantibodies and decreased HLA mediated susceptibility.
Children with Down’s syndrome (DS) are at increased risk of thyroid (1), gut (2) and islet autoimmunity (3, 4). In the only population-based study which has addressed the prevalence of Down’s syndrome in type 1 diabetes patients, a more than fourfold increased prevalence was observed (5). It has been suggested that diabetes in children with DS presents particularly early in life; one study from the 1960s showed a peak onset of 8 years of age, compared with 14 years in cases of childhood diabetes (6). In a previous study of DS and diabetes, 22% of participants had developed diabetes by the age of 2 years, compared with only 7% of those with type 1 diabetes from the general population (7). A recent study of 159 DS children diagnosed with type 1 diabetes (DSD) demonstrated two peaks in diabetes incidence, one occurring before the age of 2 years and the other in early adolescence. The mean age at onset in the 41,983 controls with type 1 diabetes was 8.42 years. (8). These data suggest that diabetes occurring before the age of 2 years in DS children may be aetiologically different from type 1 diabetes. In the seminal study of type 1 diabetes pathology by Foulis et al. (9), three cases of DS and diabetes were described. A 14 year old boy with longstanding diabetes and a 12 year old with recent-onset diabetes both showed evidence of lymphocytic infiltration with an absence of insulin staining in the 14 year old boy, typical of type 1 diabetes. The third DS child however, diagnosed with diabetes at 18 months whose pancreas was analysed within 2 weeks of diagnosis of diabetes, displayed normal insulin staining with no morphological abnormality.

An age-related association between the HLA class II susceptibility haplotypes, DRB1*04-DQB1*0302 (DR4-DQ8) and DRB1*03-DQB1*0201(DR3-DQ2) and type 1 diabetes in the general population is well established, with an increased
frequency in young children with type 1 diabetes (10, 11). These haplotypes also appear to contribute to susceptibility to diabetes in DS, but to a lesser degree (12).

The aim of this study therefore was to test the hypothesis that diabetes diagnosed before the age of 2 years does not have an autoimmune basis in a well characterised cohort of individuals with DSD. Distinguishing whether insulin deficiency in these young children is caused by accelerated autoimmunity or an alternative mechanism such as beta cell secretary deficit could have consequences for treatment or provide insights into a more aggressive autoimmune process in children with DS.
Research design and methods

Study populations

Down syndrome and diabetes

An international collection of clinical details, genetic and serum samples from children with DSD (Diaploidy) was established in 2010. In the UK, a call for potential participants in a study of diabetes in children with DS was sent out by the Diabetes Research Network and Diabetes UK. Internationally, a call was sent out through the International Society for Pediatric and Adolescent diabetes (ISPAD). All cases referred were accepted. By June 2012, 136 individuals with DS and a clinical diagnosis of type 1 diabetes had been registered (80 from the UK, 30 from Austria and Germany, 7 from other European countries and Australia, and 19 from Kuwait. Clinical data on age at diagnosis of diabetes, thyroid disease and celiac disease, family history of autoimmunity, treatment history and current height and weight were collected by questionnaire.

Control groups: Three control groups were studied as follows:

(a) Down’s syndrome controls

Blood samples were taken from 30 non-diabetic school-aged children with DS (15 male, 15 female, age range 4 - 21 years) during routine thyroid screening in the area covered by the Gloucestershire Health Authority, UK. Aliquots of DNA samples from 83 children with DS had been collected as controls for a study of congenital heart disease in DS (13). 109 DNA samples were also available for analysis from a
population-based study of children with DS in Manchester, UK (14). There was no clinical evidence of diabetes in any of these children.

(b) Type 1 diabetes controls
For the HLA analysis, two age at onset and sex-matched children with type 1 diabetes for each child with DS and diabetes were randomly selected from the population-based Bart’s Oxford (BOX) study of type 1 diabetes ongoing since 1985 with 95% ascertainment (15). Age-at-onset data from 1,822 probands diagnosed under the age of 21 years from this cohort were used to compare with age-at-onset of the DSD cohort.

(c) Healthy control subjects
HLA genotypes from 621 adult white UK controls with no history of autoimmune disease were kindly sent to us by Professor Steven Gough at the Institute of Biomedical Research, University of Birmingham, UK and have been described previously (16).

Ethical permission
Ethical permission had been granted for all studies described and written informed consent was obtained from the participant, parent or guardian, as appropriate, for all samples collected (MREC/02/6/26).

Genetic Analysis
DNA samples were genotyped for all HLA class II HLA DRB1 and DQB1 haplotypes by polymerase chain reaction using a DYNAL reli SSO system (Invitrogen DYNAL)
UK). $DRB1*04$ alleles were subtyped using the polymerase chain reaction with sequence specific primers. Haplotypes were derived from established patterns of linkage disequilibrium. The established type 1 diabetes-associated haplotype $HLA\ DRB1*0401-DQB1*0302$ was abbreviated to $DR4-DQ8$ and $HLA\ DRB1*03-DQB1*0201$ abbreviated to $DR3-DQ2$. Non-risk haplotypes were described as X. Analysis of HLA data was restricted to individuals with DSD diagnosed under the age of 21 years to avoid the issue that some older individuals with DSD may have type 2 diabetes and to allow age-matching with individuals participating in the Bart’s Oxford study of type 1 diabetes (11).

**Islet autoantibody analysis**

Antibodies to GAD65 (GADA), IA-2ic (IA-2A) and ZnT8RA/WA were measured by radioimmunoassay as previously described (15, 17). The laboratory defined assay sensitivities and specificities of GADA were 86% and 99%, and of IA-2A 72% and 93% respectively, in the Third Diabetes Antibody Standardization Program (18). The inter-assay coefficient of variation was 9% at 14 WHO units/ml (GADA), 14% at 10 WHO units/ml (IA-2A), 16% for ZnT8RA and 27% for ZnT8WA, both at 1.8 units. Serum samples were available on 43 individuals with DSD. Due to the nature of the Diaploidy cross-sectional study design, serum samples collected at diagnosis were not available for analysis. Time from diagnosis ranged from 1-396 months (median 89 months), samples collected within 10 years of diagnosis were available from 23 individuals and, a further 20 samples were collected between 10 and 39 years from diagnosis. Positivity for islet autoantibodies would be supportive of an autoimmune aetiology, while a negative post diagnosis result could not be interpreted.
Data analysis

Differences in age-at-onset and frequencies of HLA class II genotypes in children with DS and diabetes compared to age-matched children with type 1 diabetes were analysed using the chi-squared test.

Results

Down’s syndrome and diabetes: subject characteristics

Of 136 individuals with DSD, 69 (51%) were male. Data on clinical diagnosis of other autoimmune diseases were available on 92. Of these 68 (74%), had co-existing thyroid disease and 11 (14%) had co-existing celiac disease. Seven of 92 (8%) had co-existing diagnoses of diabetes, thyroid and celiac disease.

Age-at-onset analysis in the DS and diabetes population

Of 118 patients with DSD diagnosed with diabetes under the age of 21 years, 22% were diagnosed with diabetes under the age of 2 years compared with 5% of 1822 individuals with type 1 diabetes from the general population notified to the BOX study in the same age group (p<0.0001). As shown in Fig 1, there was a biphasic pattern in age at diagnosis, with a peak at 1 year of age and another centred around 10 years of age.

HLA class II analysis

In the healthy control cohort, only 3% had the highest risk diplotype (DR4-DQ8/DR3-DQ2), 13% had DR4-DQ8/X, 27% had DR3-DQ2/X and 57% had no risk haplotypes. HLA class II frequencies in the DS control population were very similar to the healthy control population as shown in figure 2a. As expected the risk haplotypes were
increased in 194 individual with type 1 diabetes age and sex-matched with the DSD population: 38% had **DR4-DQ8/DR3-DQ2**, 40% had DR4-DQ8/X, 17% had DR3-DQ2/X and 5% had no risk haplotypes. Genetic samples were available on 97 individuals with DSD diagnosed before the age of 21 years. HLA frequencies in the DSD cohort were intermediate between the type 1 diabetes and control cohorts. Specifically, 17 (17%) had the highest risk diplotype (**DR4-DQ8/DR3-DQ2**); 23 (24%) and 31 (32%) had the moderate risk DR4-DQ8 and DR3/DQ2 haplotypes respectively and 26 (27%) had no risk haplotypes. In contrast, 5% of 194 age and sex-matched children with type 1 diabetes from the BOX study (p<0.0001) and 64% of 222 DS individuals had no risk haplotypes (Figure 2a). The frequency of the **HLA-DR3-DQ2/X** diplotype (where X is not **DR4-DQ8** or **DR3-DQ2**) in DSD (32%) however, was increased relative to age-matched patients from the BOX study (17%, p=0.004).

There was no difference in HLA-mediated risk in DS children who had developed diabetes before and after the age of 2 years (Figure 2b) indicating that diabetes in the early-onset cases is unlikely to be aetiologically distinct from the diabetes found in older DS children.

**Islet autoantibodies**

Despite the extended diabetes duration at the time many samples were collected, islet autoantibodies were detected in 72% of the DSD patients for whom serum was available (Table 1). Further, all 5 samples from DSD children diagnosed before the age of 2 years, were positive for GADA.
Conclusions

In this study, we hypothesised that some early-onset cases of diabetes in DS children are not autoimmune. A biphasic distribution in age-at-onset of diabetes in children with DS previously observed in a European study of 159 children with DS and diabetes compared with 42,000 age-matched individuals with type 1 diabetes (8) was confirmed in our study. We also demonstrated, in the largest analysis to date, that T1D associated HLA genotypes are decreased in children with DSD. To account for this difference in HLA frequencies, we hypothesised that diabetes in some children diagnosed under the age of 2 years may be aetiologically different from autoimmune type 1 diabetes. Analysis of HLA data by age-at-onset however, did not support this hypothesis. This shows that DS children with early-onset diabetes are unlikely to have an aetiologically distinct form of diabetes. Two children diagnosed within the first month of life may have an alternative aetiological basis for their diabetes; the remainder were diagnosed at, or after, the age of 6 months, consistent with type 1 diabetes (19). Autoimmunity was supported by data obtained from post-diagnosis analysis of islet autoantibodies: antibodies to GAD were detected in all 5 serum samples tested from children diagnosed with diabetes under the age of 2 years. While we cannot rule out the possibility that some individuals with DS and early onset diabetes have an aetiologically distinct form of diabetes, we suggest that this is rare and may present in the first 6 months of life.

Our previous study of diabetes in 40 DS children (12) suggested that the frequency of autoimmune diabetes-associated HLA class II genotypes was increased in DSD but to a lesser extent than might be expected. We confirmed, within a substantially enlarged
sample, that the frequency of autoimmune-related HLA genotypes were decreased with a concomitant increase in non-autoimmune related genotypes in children with DSD compared with age matched children with type 1 diabetes. In young European populations with type 1 diabetes, 5-10% of individuals do not carry DR4-DQ8 and/or DR3-DQ2 (10, 11) but this proportion was increased to 27% in our similarly aged cohort of patients with DSD. This difference was not explained by the inclusion of 19 children with DS and diabetes from Kuwait, a population where HLA mediated susceptibility to diabetes may be different, as the pattern was the same when these individuals were removed from the analysis. This increased penetrance of low risk HLA class II haplotypes in DSD children mirrors the trend observed in the general population as type 1 diabetes incidence is increasing (20-23). Understanding how autoimmunity occurs in the absence of HLA risk genotypes in children with DS could therefore provide important insights into disease mechanisms in the general population.

There are limitations to this work. Although it is the largest existing cohort of individuals with DS and diabetes on whom serum and DNA is available, the Diaploidy study is relatively small. This is however a difficult group to recruit as co-occurrence of both conditions is rare. The cohort is not population based and definitive studies of incidence are not therefore possible. Analysis of islet autoantibodies years after diagnosis is not ideal, as antibody levels tend to fall post diagnosis, although antibodies to GAD are known to be the most persistent (24). Indeed, in this study at least one islet autoantibody was detectable in 75% of post-diagnosis samples, with multiple islet autoantibody positivity detectable in serum from 8 individuals more than 10 years after diagnosis.
There is a wide variation in reported prevalence rates of thyroid disorders in the Down’s syndrome population. The prevalence of autoimmune thyroid disease has been reported to be at least four-fold higher in children with DS than in the general population (25-27) but a recent longitudinal study suggests that this may be an overestimation (28). Celiac disease may be 10 times more common in DS populations (2, 29). Our study suggests that individuals with DS are at risk of extreme autoimmunity: co-occurrence of clinically diagnosed thyroid disease and diabetes was observed in 74% while clinically diagnosed celiac disease and diabetes was observed in 14% of individuals with DSD. This was based on data collected by questionnaire. The precise aetiology of thyroid disease is therefore unclear and data on anti-thyroid antibodies at diagnosis are unavailable.

Overall, a clinical picture of DSD is emerging with earlier onset diabetes, co-existence of other organ specific autoimmune diseases with persistent islet autoantibodies and decreased HLA mediated susceptibility – why might this be? Over-expression of type 1 diabetes associated genes on chromosome 21 combined with generalised immunological dysfunction in DS appears probable. GWAS identified (30) and replicated (31) a chromosome 21q22.3 type 1 diabetes associated locus . The candidate gene is the Ubiquitin associated and SH3 domain containing A (UBASH3A) which is expressed in spleen and peripheral blood lymphocytes (32) and regulates T cell signalling (33, 34). Over-expression of UBASH3A may therefore provide one candidate for the increased frequency of autoimmune disease in Down’s syndrome. Immune cell dysfunction in DS is well established. A smaller thymus in DS children has been reported several times (35, 36) and total lymphocyte numbers,
including CD4 and CD8 T cell subsets are decreased, particularly in the first two years of life. Recent analysis of protein and gene expression in surgically removed thymuses from 14 DS patients compared with 42 age-matched controls showed reduced expression of AIRE, a chromosome 21 gene product that regulates ectopic expression of tissue specific antigens in thymic medullary epithelial cells, a crucial mechanism for thymic T cell selection (37). This mechanism could contribute to the increased risk of multiple autoimmunity and the earlier onset of diabetes that we have observed.

In conclusion, diabetes in DS children is associated with a lower frequency of high risk HLA class II susceptibility genes than children matched for age-at-onset of diabetes with type 1 diabetes from the general population but this is not caused by a subset of children with an aetiologically different early onset form of diabetes. HLA DR3-DQ2/X combinations are increased in DSD children, but this does not fully explain their very high rates of endocrine autoimmunity. Our data show high rates of co-existing organ specific autoimmunity with a high prevalence of residual islet autoimmunity and lower frequencies of class II HLA diabetes susceptibility haplotypes in DSD. Understanding how this occurs may provide insights into the mechanisms underlying type 1 diabetes in the general population.
ACKNOWLEDGEMENTS

We are extremely grateful to all individuals with DS and diabetes who participated in this study. We acknowledge the help of the DS society, UK and the Diabetes Research Network for help in identifying individuals with DS and diabetes from the general UK population. We are also grateful to the clinicians who contributed samples and data to this study. R.J.A., K.L.M., J.B. J.P.H.S and K.M.G. researched data and wrote the manuscript. K.M.G. conducted analyses. AW, PJB, RWH, TR, ES, and MMAR coordinated sample collection and analysis. AW and PJB contributed to discussion. All authors reviewed, edited, and discussed the draft manuscript.

No potential conflicts of interest relevant to this article were reported.

Dr Kathleen Gillespie is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

We acknowledge the excellent technical assistance of Kyla Chandler, University of Bristol and Saba Rokni, University of Bristol and the administrative support of Dr. Claire Matthews, University of Bristol. KMG is the guarantor of this manuscript.

This work was funded by grants from EFSD/Novo Nordisk/JDRF (to KMG), the Halley Stewart Charitable Trust (to KMG) and the German Ministry of Education and Research (BMBF) Competence Network Diabetes Mellitus (FKZ 01GI0859 to RWH).
REFERENCES

Table 1: Residual islet autoantibody positivity in 43 individuals with DSD from whom serum was available.

<table>
<thead>
<tr>
<th>Time from Diagnosis</th>
<th>3 islet Ab</th>
<th>2 islet Ab</th>
<th>GADA alone</th>
<th>IA-2A alone</th>
<th>ZNT8R/W alone</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10 yrs</td>
<td>2 (11%)</td>
<td>4 (21%)</td>
<td>7 (37%)</td>
<td>0</td>
<td>0</td>
<td>6 (31%)</td>
</tr>
<tr>
<td>&gt;10 yrs</td>
<td>2 (8%)</td>
<td>6 (25%)</td>
<td>9 (38%)</td>
<td>1 (4%)</td>
<td>0</td>
<td>6 (25%)</td>
</tr>
</tbody>
</table>

**Figure legends**

**Figure 1:** (a) Age at diagnosis of diabetes in individuals with Down’s syndrome diagnosed with diabetes compared with (b) individuals with type 1 diabetes from the BOX study.

**Figure 2:** (a) The frequency (%) of type 1 diabetes associated haplotypes in children with Down’s syndrome and diabetes (DSD) relative to age-matched children with type 1 diabetes (T1D), DS alone and healthy control subjects (HC).

(b) The HLA characteristics of diabetes in children with Down’s syndrome by age at onset compared with type 1 diabetes.